Cd34 Immunohistochemical Assessment of Angiogenesis as a Prognostic Marker for Prostate Cancer Recurrence After Radical Prostatectomy

Bettencourt, Marie-Claude; Bauer, John J.; Sesterhenn, Isabella A.; Connelly, Roger R.; Moul, Judd W.

doi:10.1097/00005392-199808000-00047

Cited by 42 publications

(63 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recently reported strong association of high macrophage index with a better post-operative outcome in prostate cancer patients contrasts the postulated 'angiogenic role' of macrophages (Shimura et al, 2000). High angiogenesis is an important variable of poor prognosis in prostate carcinomas, as has been convincingly shown in a large number of studies (Silberman et al, 1997;Bettencourt et al, 1998;Borre et al, 1998;Strohmeyer et al, 2000;Mehta et al, 2001). Specific intratumoural conditions (cytokines released by cancer cells, fibroblasts or even by tumour related lymphocytes) may form a complex code that switches on/off or even reverses the macrophage angiogenic machinery.…”

Section: Molecular and Cellular Pathologymentioning

confidence: 81%

“…Once activated by these stimuli, endothelial cells proliferate, migrate and, eventually, differentiate into functioning capillaries (Pinedo and Slamon, 2000). In prostate carcinomas, as in other tumours, an increased angiogenesis, assessed as microvessel density (MVD), is usually connected with poor prognosis (Hall et al, 1994;Bettencourt et al, 1998;Offersen et al, 1998;Strohmeyer et al, 2000a,b).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis

et al. 2002

View full text Add to dashboard Cite

Thymidine phosphorylase is an angiogenic factor primarily expressed by cancer cells, stromal cells and tumour-associated macrophages in many human malignancies. These different types of thymidine phosphorylase-expressing cells, however, may have a distinct place in the angiogenic process, and this question was addressed in the present study. A series of 20 normal/ hyperplastic prostate glands and 60 prostate carcinomas was investigated by immunohistochemistry, using specific antibodies for thymidine phosphorylase (P-GF.44C), tumour-associated macrophages (CD68), endothelium (CD31) and prostate specific antigen (ER-PR8). Thymidine phosphorylase expression by normal and hyperplastic epithelial or stromal cells occurred almost exclusively in the context of an intense lymphocytic infiltrate. High thymidine phosphorylase cancer cells and thymidine phosphorylase stromal cells expression was associated with high angiogenesis in prostate carcinomas, and this significant association was extended to include both tumour-associated macrophages and tumour-infiltrating lymphocytes. Thymidine phosphorylase expression and tumour-infiltrating lymphocytes were related inversely with prostate specific antigen reactivity. In conclusion, thymidine phosphorylase is a major angiogenic factor in prostate carcinomas and its up-regulation is likely to occur in the context of a host immune response.

show abstract

Section: Molecular and Cellular Pathologymentioning

confidence: 81%

mentioning

confidence: 99%

Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Some authors (8,21,22) have established a quantitative relationship between tumor neovascularization with recurrence and progression in prostate cancer, although others have not found correlation with clinical outcome (23). Tumor microvessel density/vascular endothelial growth factor expression has also been shown to predict biologic behavior in prostatic cancer (24,25).…”

Section: Discussionmentioning

confidence: 99%

Increased Cellularity of Tumor-Encased Native Vessels in Prostate Carcinoma Is a Marker for Tumor Progression

et al. 2000

View full text Add to dashboard Cite

Changes in the native vasculature of the prostate gland associated with prostate adenocarcinoma have not been well characterized. Eighty-nine whole mounts of entirely submitted radical prostatectomies were reviewed. Thirty prostates with a minimum of five native arteries surrounded by carcinoma with corresponding control arteries were found and included in this study. The number of nuclei in the media of native arteries was recorded per 0.138 mm 2 using a 40؋ objective.The number of nuclei in vessels embedded in carcinoma (n ‫؍‬ 204) was increased when compared with controls (26.37 versus 20.58 mean nuclei per 0.138 mm 2 ; P < .001). Pathologic Stage T3 carcinomas contained vessels that were more cellular than stage T2 (P < .001). Vessels embedded in Gleason Grade 4 showed more cellularity than arteries embedded in Gleason Grade 3 (P < .002).Increased media cellularity of native prostate vessels encased in carcinoma is a histologic feature of higher grade/stage prostate carcinoma and provides positive indicator of advanced prostate cancer.

show abstract

“…16 Any dark staining endothelial cell or cell cluster clearly separate from adjacent structures was considered a single vessel. For practical purposes, tumors were arbitrarily divided into two groups: one with microvessel counts less than or equal to 90 per 2006microscopic field ( Figure 1A), the second with microvessel counts superior to 90 per 2006microscopic field 15 ( Figure 1B). This two-level classification of density was made independently by two researchers (MS and NC) without knowledge of the clinical course of the disease.…”

Section: Methodsmentioning

confidence: 99%

“…13 -15 In more recent studies it has also been demonstrated that CD34 quantifies MVD in PC and that it can be useful to identify patients at high-risk of recurrence after radical prostatectomy. 15 The purpose of the present study was to see whether there is a correlation between MVD, assessed by the analysis of CD34 immunoreactivity and disease recurrence (biochemical or clinical) in a series of patients who underwent radical prostatectomy (RP).…”

Section: Introductionmentioning

confidence: 99%

Microvessel density in prostate carcinoma

Bono

Celato

Cova

et al. 2002

Prostate Cancer Prostatic Dis

137

111

View full text Add to dashboard Cite

The objective of this work was to assess the correlation between microvessel density (MVD), pathological stage and disease recurrence in a series of patients who underwent radical prostatectomy for prostate cancer. Pathological material from 75 consecutive radical prostatectomies performed before 1994 without neoadjuvant treatment, in which sufficient follow-up data were available, was reexamined. Paraffin embedded material was re-cut and hematoxylin and eosin (H&E) stained. Areas of maximal angiogenesis within tumor were identified. Expression of CD34 was investigated by using the monoclonal antibody MY 10. Within the areas of maximal angiogenesis, microvessels expressing CD34 were counted and specimens were divided into two groups, one showing a count of less than 90 microvessels per microscopic field at 2006magnification (MVD < 90), the second more than 90 microvessels (MVD > 90). The MVD was then related to pathological stage, Gleason score (GS) and outcome of the disease. Mean followup was 84 months. Clinical or biochemical progression was observed in 38.6% of patients. In low GS cases, MVD was always < 90, whereas in GS 5 -6, half had MVD < 90 and half were > 90. In high GS MVD was always > 90. MVD was positively associated with a higher pathological stage. Progression of the disease was observed in 20% of MVD < 90 and in 51% in MVD > 90 (P ¼ 0.006). MantelHaensz test showed a correlation between MVD and time to progression (P < 0.05). Although problems exist in methods of counting and in the cut-off number of vessels, which can discriminate the risk categories, it may be concluded that microvessel counts, using CD34 monoclonal antibody, can accurately predict the outcome of radical prostatectomy.

show abstract

Cd34 Immunohistochemical Assessment of Angiogenesis as a Prognostic Marker for Prostate Cancer Recurrence After Radical Prostatectomy

Abstract: Microvascularity or neovascularity as measured by the CD34 antigen may be a prognostic marker of recurrence for prostate cancer patients after radical prostatectomy but more study in prostate specific antigen era patients with sufficient followup is needed.

Cited by 42 publications

References 20 publications

Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis

Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis

Increased Cellularity of Tumor-Encased Native Vessels in Prostate Carcinoma Is a Marker for Tumor Progression

Microvessel density in prostate carcinoma

Contact Info

Product

Resources

About